This combination may be effective in AKT or PTEN mutant breast cancer (26).More recently, it has been shown that proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes endocrine therapy resistance in breast cancer, suggesting that the ER+/PRR11-amplified breast cancers subgroup of tumors can also benefit from treatment with PI3K inhibitors and antiestrogens (27). This evidence concerns the gene AKT1 and breast carcinoma.